Breaking News

AI Drug Turnaround Startup, Ignota Labs, Raises $6.9M

Identifies promising drug candidates that have been abandoned due to safety concerns and uses SAFEPATH to determine the underlying issues and develop solutions.

Author Image

By: Charlie Sternberg

Associate Editor

L to R: Ignota Labs Co-Founders Dr. Jordan Lane, Chief Scientific Officer; Sam Windsor, Chief Executive Officer; and Dr. Layla Hosseini-Gerami, Chief Data Science Officer.

Ignota Labs, an AI-driven drug turnaround company, has closed a $6.9 million seed funding round, co-led by Montage Ventures and AIX Ventures with participation from Modi Ventures, Blue Wire Capital and Gaingels. The funding will be used to expand its pipeline by acquiring additional distressed assets and for advancement into early-stage clinical trials of its first asset, a PDE9A inhibitor. Drug safety failures are a leading cause of clinical trial failures. Ignota Labs addresses this issue b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters